The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I,

##STR00001##

and the variables R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification.

Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

The invention provides compounds of formula I: and salts thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating cancer using compounds of formula I. ##STR00001##

Inhibitors of HBV replication of Formula (I-A)

##STR00001##

including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R.sup.a to R.sup.d, and R.sup.1 to R.sup.8 have the meaning as defined herein.

The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.

##STR00001##

The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.

##STR00001##

The invention provides compounds of Formula (I) ##STR00001##
as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

A Spiro compound serving as an ERK inhibitor, and an application thereof in preparing a drug for treating an ERK-related disease. The present invention specifically relates to a compound represented by formula (III) or a pharmaceutically acceptable salt thereof. ##STR00001##

A Spiro compound serving as an ERK inhibitor, and an application thereof in preparing a drug for treating an ERK-related disease. The present invention specifically relates to a compound represented by formula (III) or a pharmaceutically acceptable salt thereof. ##STR00001##